Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19723682 | 0.86 | SMN1; SMN2 (0.49) | KMT2ASMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL6112657 | 0.84 | KMT2A (0.64) | KMT2ASMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL23574175 | 0.84 | SMN1; SMN2 (0.47) | KMT2ASMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL4538242 | 0.79 | KMT2A (0.57) | KMT2ASMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL7976885 | 0.78 | MAPT (0.46) | KMT2ASMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL19723655 | 0.78 | SMN1; SMN2 (0.44) | KMT2ASMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL7974317 | 0.78 | KMT2A (0.56) | KMT2ASMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL7981619 | 0.77 | KMT2A (0.55) | KMT2ASMN1; SMN2MAPTHTTMAPK1 | |
| SCHEMBL19723523 | 0.76 | CYP2C9 (0.57) | KMT2ASMN1; SMN2LMNAHTTNPC1 | |
| SCHEMBL19723781 | 0.76 | SMN1; SMN2 (0.49) | KMT2ASMN1; SMN2LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | KMT2A 216/4885SMN1; SMN2 3263/4885LMNA 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.